CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING ANTIRETROVIRAL THERAPY ADMINISTERED EVERY 2-MONTHS IS COST EFFECTIVE FOR THE TREATMENT OF HIV-1 IN SPAIN

被引：0
|
作者：
Moreno Guillen, S. [1 ]
Rivero, A. [2 ]
Ventayol, P. [3 ]
Falco, V. [4 ]
Torralba, M. [5 ]
Schroeder, M. [6 ]
Neches, V. [7 ]
Vallejo-Aparicio, L. A. [7 ]
Mackenzie, I. [8 ]
Turner, M. [9 ]
Harrison, C. [9 ]
机构：
[1] Hosp Ramon & Cajal, Madrid, Spain
[2] Hosp Reina Sofia, Cordoba, Spain
[3] Hosp Univ Son Espases, Palma De Mallorca, Spain
[4] Hosp Valle De Hebron, Barcelona, Spain
[5] Hosp Univ Guadalajara, Guadalajara, Spain
[6] ViiV Healthcare, Brentford, England
[7] GSK, Tres Cantos, Spain
[8] Hlth Econ & Outcomes Res Ltd, Stratford Upon Avon, War, England
[9] Hlth Econ & Outcomes Res Ltd, Cardiff, Crf, Wales
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE345
引用
收藏
页码：S122 / S122
页数：1
相关论文
共 50 条
  • [1] Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
    Moreno, Santiago
    Rivero, Antonio
    Ventayol, Pere
    Falco, Vicenc
    Torralba, Miguel
    Schroeder, Melanie
    Neches, Victoria
    Vallejo-Aparicio, Laura Amanda
    Mackenzie, Isaac
    Turner, Matthew
    Harrison, Cale
    INFECTIOUS DISEASES AND THERAPY, 2023, 12 (08) : 2039 - 2055
  • [2] Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2 Months is Cost-Effective for the Treatment of HIV-1 in Spain
    Santiago Moreno
    Antonio Rivero
    Pere Ventayol
    Vicenç Falcó
    Miguel Torralba
    Melanie Schroeder
    Victoria Neches
    Laura Amanda Vallejo-Aparicio
    Isaac Mackenzie
    Matthew Turner
    Cale Harrison
    Infectious Diseases and Therapy, 2023, 12 : 2039 - 2055
  • [3] COST-EFFECTIVENESS OF LONG-ACTING CABOTEGRAVIR PLUS LONG-ACTING RILPIVIRINE FOR THE TREATMENT OF HIV-1 IN TAIWAN
    Wen, Y. C.
    Ou, H. T.
    Tien, K.
    Harrison, C.
    Omonmhenle, D.
    Turner, M.
    Anderson, S. J.
    Jacob, I
    VALUE IN HEALTH, 2023, 26 (06) : S145 - S145
  • [4] Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
    Swindells, Susan
    Andrade-Villanueva, Jaime-Federico
    Richmond, Gary J.
    Rizzardini, Giuliano
    Baumgarten, Axel
    Masia, Mar
    Latiff, Gulam
    Pokrovsky, Vadim
    Bredeek, Fritz
    Smith, Graham
    Cahn, Pedro
    Kim, Yeon-Sook
    Ford, Susan L.
    Talarico, Christine L.
    Patel, Parul
    Chounta, Vasiliki
    Crauwels, Herta
    Parys, Wim
    Vanveggel, Simon
    Mrus, Joseph
    Huang, Jenny
    Harrington, Conn M.
    Hudson, Krischan J.
    Margolis, David A.
    Smith, Kimberly Y.
    Williams, Peter E.
    Spreen, William R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (12): : 1112 - 1123
  • [5] The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment
    Alberton, Francesca
    Nozza, Silvia
    Raccagni, Angelo Roberto
    Galli, Laura
    Spagnuolo, Vincenzo
    Bossolasco, Simona
    Cernuschi, Massimo
    Canetti, Diana
    Hasson, Hamid
    Castagna, Antonella
    Gianotti, Nicola
    JOURNAL OF MEDICAL VIROLOGY, 2023, 95 (01)
  • [6] A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
    Bares, Sara H.
    Scarsi, Kimberly K.
    CURRENT OPINION IN HIV AND AIDS, 2022, 17 (01) : 22 - 31
  • [7] Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy
    D'Amico, Ronald
    Gomis, Santiago Cenoz
    Moodley, Riya
    Van Solingen-Ristea, Rodica
    Baugh, Bryan
    Van Landuyt, Erika
    Van Eygen, Veerle
    Min, Sherene
    Cutrell, Amy
    Foster, Caroline
    Chilton, Daniella
    Allard, Sabine D.
    Ruiter, Annemiek
    HIV MEDICINE, 2023, 24 (02) : 202 - 211
  • [8] Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
    Orkin, Chloe O. C.
    Arasteh, Keikawus A. K.
    Hernandez-Mora, M. Gorgolas M. G. H. M.
    Pokrovsky, Vadim P. V.
    Overton, Edgar T. O. E. T.
    Girard, Pierre-Marie G. P. M.
    Oka, Shinichi O. S.
    Walmsley, Sharon W. S.
    Bettacchi, Chris B. C.
    Brinson, Cynthia B. C.
    Philibert, Patrick P. P.
    Lombaard, Johan L. J.
    Clair, Marty C. M.
    Crauwels, Herta C. H.
    Ford, Susan L. F. S. L.
    Patel, Parul P. P.
    Chounta, Vasiliki C. V.
    D'Amico, Ronald D. R.
    Vanveggel, Simon V. S.
    Dorey, David D. D.
    Cutrell, Amy C. A.
    Griffith, Sandy G. S.
    Margolis, David A. M. D. A.
    Williams, Peter E. W. P. E.
    Parys, Wim P. W.
    Smith, Kimberly Y. S. K. Y.
    Spreen, William R. S. W. R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (12): : 1124 - 1135
  • [9] Long-acting cabotegravir/rilpivirine as a safe antiretroviral therapy in solid organ transplanted HIV patients
    Moreno, Ana
    Del Campo, Santos
    Jesus Perez-Elias, Maria
    Luis Casado, Jose
    Garcia, Miguel
    Velez, Manuel
    Jesus Vivancos, Maria
    Moreno, Santiago
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 82 - 82
  • [10] Cabotegravir and rilpivirine concentrations and HIV-1 RNA suppression in male and female genital fluids and rectal tissue in people with HIV on antiretroviral therapy with long-acting intramuscular cabotegravir plus rilpivirine
    Fernandez, Analuz
    Scevola, Sofia
    Niubo, Jordi
    Sykes, Craig
    Schauer, Amanda P.
    Piatti, Camila
    Morenilla, Sandra
    Sedo, Alicia
    Soriano, Irene
    Garcia, Benito
    Medina, Daniel
    Tiraboschi, Juan
    Saumoy, Maria
    Cottrell, Mackenzie L.
    Imaz, Arkaitz
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 3 - 4
12345